Histamine dihydrochloride injection - Immune Pharmaceuticals

Drug Profile

Histamine dihydrochloride injection - Immune Pharmaceuticals

Alternative Names: Ceplene; Maxamine

Latest Information Update: 24 Jun 2017

Price : $50

At a glance

  • Originator EpiCept Corporation
  • Developer EpiCept Corporation; Immune Pharmaceuticals Inc; Karolinska University Hospital; MegaPharm Ltd; Nordic Group; Sahlgrenska University Hospital
  • Class Antineoplastics; Antivirals; Imidazoles; Small molecules
  • Mechanism of Action NADPH oxidase inhibitors; Oxygen radical formation antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia; Malignant melanoma
  • New Molecular Entity No

Highest Development Phases

  • Marketed Acute myeloid leukaemia
  • Phase I/II Chronic myelomonocytic leukaemia
  • Preclinical Solid tumours
  • Discontinued Alcoholic hepatitis; Hepatitis C; Malignant melanoma; Non-alcoholic steatohepatitis

Most Recent Events

  • 20 Apr 2017 Immune Pharmaceuticals and Pint Pharma sign letter of intent to commercialise histamine dihydrochloride injection in Latin America, Argentina, Brazil, Chile, Colombia and Mexico
  • 15 Feb 2017 Phase-I/II clinical trials in Chronic myelomonocytic leukaemia (Combination therapy) in Sweden (SC) (NCT03040401)
  • 17 Aug 2016 Efficacy data from a phase IV trial in Acute myeloid leukaemia (Combination therapy) released by Immune Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top